Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 56.81 USD -0.58% Market Closed
Market Cap: 115.2B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Gross Margin
Bristol-Myers Squibb Co

75.9%
Current
78%
Average
48.5%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
75.9%
=
Gross Profit
36B
/
Revenue
47.4B

Gross Margin Across Competitors

Country US
Market Cap 115.2B USD
Gross Margin
76%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 747.7B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.8T DKK
Gross Margin
85%
Country US
Market Cap 342.5B USD
Gross Margin
69%
Country US
Market Cap 252.8B USD
Gross Margin
77%
Country CH
Market Cap 216.7B CHF
Gross Margin
73%
Country UK
Market Cap 170.3B GBP
Gross Margin
82%
Country CH
Market Cap 179.3B CHF
Gross Margin
75%
Country US
Market Cap 152.2B USD
Gross Margin
71%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Economic Moat
None
Market Cap
115.2B USD
Industry
Pharmaceuticals

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BMY Intrinsic Value
69.01 USD
Undervaluation 18%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
75.9%
=
Gross Profit
36B
/
Revenue
47.4B
What is the Gross Margin of Bristol-Myers Squibb Co?

Based on Bristol-Myers Squibb Co's most recent financial statements, the company has Gross Margin of 75.9%.